Drug Profile
PEC Encap
Alternative Names: Encapsulated human islet cell therapy - ViaCyte; Encapsulated islet cell transplantation therapy - ViaCyte; Encapsulated pancreatic cell transplantation therapy - ViaCyte; PEC-01; PEC-01 cells loaded into an Encaptra drug delivery System; PEC-EnCap; PEC-Encap™; VC-01; VC-01 Combination ProductLatest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator ViaCyte Inc
- Class Pluripotent stem cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Type 1 diabetes mellitus
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 06 Nov 2023 ViaCyte terminates a phase I/II trial in Type 1 diabetes mellitus in USA due to insufficient functional product engraftment (NCT04678557)
- 06 Dec 2021 ViaCyte terminates a phase-I/II STEP ONE clinical trial in Type-1 diabetes mellitus in USA and Canada, due to insufficient functional product engraftment (SC) (NCT02239354)
- 02 Dec 2021 Efficacy data from a phase I/II trial in Type-1 diabetes mellitus released by ViaCyte